55 / 76
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 27, No 6, November/December 2016
AFRICA
385
ischemic preconditioning.
Cardiovasc Drug Ther
2010;
24
: 225–234
(PMID: 20505987).
17. Huesch G. Molecular basis of cardioprotection: signal transduction
in ischemic pre-, post-, and remote conditioning.
Circ Res
2015;
116
:
674–699 (PMID: 25677517).
18. Karliner JS. Sphingosine kinase and sphinosine 1-phosphate in
cardioprotection.
J Cardiovasc Pharmacol
2009;
53
: 189–197 (PMID:
19247197).
19. Knapp M. Cardioprotective role of sphingosine-1-phosphate.
J Physiol
Pharmacol
2011;
62
: 601–607 (PMID: 22314562).
20. Jin Z-Q, Zhou H-Z, Zhu P, Honbo N, Mochly-Rosen D, Messing
RO,
et al
. Cardioprotection mediated by sphingosine-1-phosphate and
ganglioside GM-1 in wild-type and PKC
ε
knockout mouse hearts.
Am J
Physiol Heart Circ Physiol
2002;
282
: H1970–H1977 (PMID: 12003800).
21. Vessey DA, Li L, Kelley M, Karliner JS. Combined sphingosine,
S1P and ischemic postconditioning rescue the heart after protracted
ischemia.
Biochem Biophys Res Commun
2008;
375
: 425–429 (PMID:
18706887).
22. Vessey DA, Kelley M, Li L, Huang Y. Sphingosine protects aging hearts
from ischemia/reperfusion injury: superiority to sphingosine 1-phos-
phate and ischemic pre- and post-conditioning.
Oxid Med Cell Longev
2009;
2
: 146–151 (PMID: 20592769).
23. Somers SJ, Frias M, Lacerda L, Opie LH, Lecour S. Interplay between
SAFE and RISK pathways in sphingosine-1-phosphate-induced cardio-
protection.
Cardiovasc Drugs Ther
2012;
26
: 227–237 (PMID: 22392184).
24. Kelly-Laubscher RF, King JC, Hacking D, Somers S, Hastie S,
Stewart T,
et al
. Cardiac preconditioning with sphingosine-1-phosphate
requires activation of signal transducer and activator of transcription-3.
Cardiovasc J Afr
2014;
25
: 118–123 (PMID: 25000441).
25. Chun J, Brinkmann V. A mechanistically novel, first oral therapy for
multiple sclerosis: the development of Fingolimod (FTY720, Gilenya).
Discov Med
2011;
12
: 213–228 (PMID: 21955849).
26. Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic
effects in the immune and the central nervous system.
Br J Pharmacol
2009;
158
: 1173–1182 (PMID: 19814729).
27. Hla T, Brinkmann V. Sphingosine 1-phosphate (S1P): physiology and
the effects of S1P receptor modulation.
Neurology
2011;
76
: S3–S8
(PMID: 21339489).
28. Egom EEA, Ke Y, Musa H, Mohamed TMA, Wang T, Cartwright E,
et
al
. FTY720 prevents ischemia/reperfusion injury-associated arrhythmias
in an
ex vivo
rat heart model via activation of Pak1/Akt signaling.
J
Molec Cell Cardiol
2010;
48
: 406–414 (PMID: 19852968).
29. Hofmann U, Hu K, Walter F, Burkard N, Ertl G, Bauersachs J,
et al
.
Pharmacological pre- and post-conditioning with the sphingosine-
1-phosphate receptor modulator FTY720 after myocardial ischaemia–
reperfusion.
Br J Pharmacol
2010;
160
: 1243–1251 (PMID: 20590616).
30. Vessey DA, Li L, Imhof I, Honbo N, Karliner JS. FTY720 postcondi-
tions isolated perfused heart by a mechanism independent of sphingo-
sine kinase 2 and different from S1P or ischemic postconditioning.
Med
Sci Monit Basic Res
2013;
19
: 126–132 (PMID: 23567658).
31. Egom EEA, Mohamed TMA, Mamas MA, Shi Y, Liu W, Chirico D,
et al
. Activation of Pak1/Akt/eNOS signaling following sphingosine-
1-phosphate release as part of a mechanism protecting cardiomyocytes
against ischemic cell injury.
Am J Physiol Heart Circ Physiol
2011;
301
:
H1487–H1495 (PMID: 21705677).
32. Hofmann U, Burkard N, Vogt C, Thoma A, Frantz S, Ertl G,
et al
.
Protective effects of sphingosine-1-phosphate receptor agonist treat-
ment after myocardial ischaemia–reperfusion.
Cardiovasc Res
2009;
83
:
285–293 (PMID: 19416991).
33. US Food and Drug Administration. Drugs@FDA: FDA approved drug
products. In:
US Food and Drug Administration.
http://www.access-data.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction
=
Search.
DrugDetails. Accessed 30 January 2014.
34. Novartis. Novartis receives European Commission approval for
Gilenya
®
, the first oral multiple sclerosis treatment for use in the EU.
In: Novartis Media Releases. 2011.
http://www.novartis.com/newsroom/media-releases/en/2011/1498377.shtml. Accessed 29 January 2014.
35. Perrotti D, Neviani P. Protein phosphatase 2A: a target for anticancer
therapy.
Lancet Oncol
2013;
14
: e229–e238 (PMID: 23639323).
36. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW,
et al
. FTY720, a new alternative for treating blast crisis chronic myelog-
enous leukemia and Philadelphia chromosome–positive acute lympho-
cytic leukemia.
J Clin Invest
2007;
117
: 2408–2421 (PMID: 17717597).
37. Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G,
et al
. Antagonistic activities of the immunomodulator and PP2A-
activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hema-
tologic malignancies.
Blood
2013;
122
: 1923–1934 (PMID: 23926298).
38. Matsuoka Y, Nagahara Y, Ikekita M, Shinomiya T. A novel immuno-
suppressive agent FTY720 induced Akt dephosphorylation in leukemia
cells.
Br J Pharmacol
2003;
138
: 1303–1312 (PMID: 12711631).
39. Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A,
Oaks J,
et al
. Sphingosine analogue drug FTY720 targets I2PP2A/SET
and mediates lung tumour suppression via activation of PP2A-RIPK1-
dependent necroptosis.
EMBO Mol Med
2013;
5
: 105–121 (PMID:
23180565).
40. Sutherland FJ, Hearse DJ. The isolated blood and perfusion fluid
perfused heart.
Pharmacol Res
2000;
41
: 613–627 (PMID: 10816330).
41. Skrzypiec-Spring M, Grotthus B, Szel
ą
g A, Schulz R. Isolated heart
perfusion according to Langendorff—Still viable in the new millennium.
J Pharmacol Toxicol Methods
2007;
55
: 113–126 (PMID: 16844390).
42. Lochner A, Genade S, Tromp E, Podzuweit T, Moolman JA. Ischemic
preconditioning and the
β
-adrenergic signal transduction pathway.
Circulation
1999;
100
: 958–966 (PMID: 10468527).
43. Kannengieser GJ, Opie LH, van der Werff. Impaired cardiac work and
oxygen uptake after reperfusion of regionally ischaemic myocardium.
J
Mol Cell Cardiol
1979;
11
: 197–207. (PMID: 423263).
44. Shlafer M, Karow AM. Pharmacological effects of dimethyl sulfoxide
on the mammalian myocardium.
Ann N Y Acad Sci
1975;
27
: 110–121
(PMID: 236711).
45. Bell JR, Eaton P, Shattock MJ. Role of p38-mitogen-activated protein
kinase in ischaemic preconditioning in rat heart.
Clin Exp Pharmacol
Physiol
2008;
35
: 126–134. (PMID: 17892505).
46. Marais E, Genade S, Salie R, Huisamen B, Maritz S, Moolman JA,
Lochner A. The temporal relationship between p38 MAPK and HSP27
activation in ischaemic and pharmacological preconditioning.
Basic Res
Cardiol
2005;
100
: 35–47 (PMID: 15526116).
47. Fan W-J, Genade S, Genis A, Huisamen B, Lochner A. Dexamethasone-
induced cardioprotection: a role for the phosphatase MKP-1?
Life Sci
2009;
84
: 838–846. (PMID: 19361533).
48. Lochner A, Genade S, Moolman JA. Ischemic preconditioning: Infarct
size is a more reliable endpoint than functional recovery.
Basic Res
Cardiol
2003;
98
: 337–346 (PMID: 12955407).
49. Salie R, Moolman JA, Lochner A. The role of
β
-adrenergic receptors in
the cardioprotective effects of beta-preconditioning (
β
PC).
Cardiovasc
Drugs Ther
2011;
25
: 31–46 (PMID: 21225332).
50. Ytrehus K. The ischemic heart – experimental models.
Pharmacol Res
2000;
42
: 193–203 (PMID: 10945923).
51. Csonka C, Kupai K, Kocsis GF, Novák G, Fekete V, Bencsik P
, et
al
. Measurement of myocardial infarct size in preclinical studies.
J
Pharmacol Toxicol Meth
2010;
61
: 163–170 (PMID: 20188845).